Identifying Rare Genetic Variants Involved in High Risk Pediatric Leukemia Via Pooled Sequencing |
Washington University / Todd Druley, MD, PhD |
'A' Award Grants |
2009 |
Missouri |
Uncovering the signaling mechanisms allowing medulloblastoma progenitor cells to orchestrate tumor relapse |
Medical University of South Carolina / Jezabel Rodriguez Blanco, PhD |
'A' Award Grants |
2023 |
South Carolina |
Synergistic Activity of Anti-GD2 Antibody and CD47-Blockade for Immunotherapy of Neuroblastoma and Osteosarcoma |
The Board of Trustees of the Leland Stanford Junior University / Robbie Majzner, MD |
'A' Award Grants |
2019 |
California |
The Role of the Innate Immune System in Immune Dysregulation following CART |
Children’s Hospital of Philadelphia / Caroline Diorio, MD |
'A' Award Grants |
2023 |
Pennsylvania |
Turning Killers into THINKers: TME Hostility-Impervious NK Cells for Treating Neuroblastoma and Sarcoma |
Baylor College of Medicine / Robin Parihar, MD/PhD |
'A' Award Grants |
2021 |
Texas |
Blockade of p53 and Aurora A in Therapy Resistant Neuroblastoma |
University of California San Francisco / William Clay Gustafson, MD, PhD |
'A' Award Grants |
2011 |
California |
Functional Characterization of RELA Fusion Ependymoma as a Basis for Therapeutic Targeting |
St. Jude Children’s Research Hospital / Stephen Mack, PhD |
'A' Award Grants |
2018 |
Tennessee |
Genetic Susceptibility to Pediatric Osteosarcoma and Interaction with Measures of Childhood Growth |
Duke University / Kyle Walsh, Ph.D. |
'A' Award Grants |
2014 |
North Carolina |
The Role of Inherited MLL3 Single Nucleotide Variants and Fetal Epigenetic Programming in Infant Leukemogenesis |
Washington University / Jeffrey Magee, MD/PhD |
'A' Award Grants |
2016 |
Missouri |
An Engineered Nanoimmunotherapy for Treating Neuroblastoma |
George Washington University / Rohan Fernandes, PhD |
'A' Award Grants |
2016 |
District of Columbia |